Julia Shapranova: Connecting Neuroscience with The Reality of Clinical Trials Leadership and Management at ESOC 2026
Julia Shapranova, Learning and Development Manager at Magnus Energy, shared on LinkedIn:
”I’ll be speaking at the European Stroke Organisation conference teaching course this May on a topic very close to my heart:
The neuroscience of leadership in high-pressure environments.
Honored that this session will be chaired by exceptional leaders in stroke care: Gustavo Saposnik, Valeria Caso, Ashkan Shoamanesh
Looking forward to being part of this scientific event and reconnecting with long-time colleagues and friends along the way.
Today, leadership is not only about how much you know or the title you hold, it’s about the state you create in others, and how well you navigate between threat and reward in the brain.
In this session, I’ll connect neuroscience with the reality of clinical trials leadership and management, focusing on:
- How to create psychological safety in high-stakes teams (and avoid bias)
- How stress and bias shape decisions under pressure
- The two fundamental human needs: to feel safe and to matter
- How to lower defenses so teams can focus on delivery
- What it takes to build functional cultures and high-performing teams
Because once people feel threatened, performance, collaboration, and creativity drop, exactly what we don’t want in clinical trials.
Resilient systems are critical in stroke care and they don’t start with strategy alone they start with how we lead and mobilize people, often in complex and unpredictable environments.
If this resonates, join our interactive workshop: ‘Neuroleadership, Management and Behavioural Insights in Stroke Care’
We’ll also explore how principles from behavioral economics and neuroeconomics can be applied in stroke care and share lessons learned from conducting clinical trials with practical tools you can apply immediately in clinical trials.
Wednesday, May 6, 2026 at 15:00 CET”

Stay updated with Hemostasis Today.
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines